Abstract
Nuclear receptors (NRs) are ligand-activated transcription factors modulating significant biological functions including cell growth, lipid metabolism, and glucose homeostasis, so they are frequently to be utilized as important drug targets to develop therapeutic reagents. Farnesoid X receptor (FXR) with bile acids as the natural ligands, plays an essential role in regulation of bile acid and glucose metabolism, and is involved in the pathologies of human diseases including diabetes and chronic liver diseases. Thus, FXR is a promising pharmacological target for these diseases. Synthetic FXR agonists like INT-747 developed by Intercept Pharmaceutical Company is in the clinical trial phase III for non-alcoholic steatohepatitis and can be approved as the treatment of primary biliary cirrhosis in 2016. Due to the promising clinical trial results of INT-747, the naturally occurring FXR ligands may be utilized as the preventive nutraceuticals or treatments of the chronic liver diseases and diabetes. In this review, the natural FXR agonists are summarized and their possible interactions with FXR ligand binding region are discussed.
Keywords: Farnesoid X receptor (FXR), FXR ligand binding region, liver, NAFLD, nuclear receptors, natural product.
Mini-Reviews in Organic Chemistry
Title:Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
Volume: 13 Issue: 2
Author(s): Hsiang-Ru Lin
Affiliation:
Keywords: Farnesoid X receptor (FXR), FXR ligand binding region, liver, NAFLD, nuclear receptors, natural product.
Abstract: Nuclear receptors (NRs) are ligand-activated transcription factors modulating significant biological functions including cell growth, lipid metabolism, and glucose homeostasis, so they are frequently to be utilized as important drug targets to develop therapeutic reagents. Farnesoid X receptor (FXR) with bile acids as the natural ligands, plays an essential role in regulation of bile acid and glucose metabolism, and is involved in the pathologies of human diseases including diabetes and chronic liver diseases. Thus, FXR is a promising pharmacological target for these diseases. Synthetic FXR agonists like INT-747 developed by Intercept Pharmaceutical Company is in the clinical trial phase III for non-alcoholic steatohepatitis and can be approved as the treatment of primary biliary cirrhosis in 2016. Due to the promising clinical trial results of INT-747, the naturally occurring FXR ligands may be utilized as the preventive nutraceuticals or treatments of the chronic liver diseases and diabetes. In this review, the natural FXR agonists are summarized and their possible interactions with FXR ligand binding region are discussed.
Export Options
About this article
Cite this article as:
Lin Hsiang-Ru, Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region, Mini-Reviews in Organic Chemistry 2016; 13 (2) . https://dx.doi.org/10.2174/1570193X13666160401000445
DOI https://dx.doi.org/10.2174/1570193X13666160401000445 |
Print ISSN 1570-193X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6298 |
Call for Papers in Thematic Issues
Active Alkaloids: Structure, Mechanism of Action, Chemical Synthesis, and Biosynthesis
The scope of this topic encompasses the structure, mechanism of action, chemical synthesis, and biosynthesis of active alkaloids. Alkaloids, a class of nitrogen-containing organic compounds with alkaline properties, originate from a diverse array of sources. Many alkaloids exhibit significant biological activities and serve as key constituents in numerous medicinal plants. ...read more
Advancement in Petroleum Geochemistry
The scope of the thematic issue on advancements in petroleum geochemistry encompasses a broad range of cutting-edge research and technological innovations. This issue aims to highlight the latest developments in understanding the chemical and physical properties of petroleum and its geological formations. Key areas of focus include: Unconventional Resources: Exploring ...read more
Advancements in Synthesis of Bioactive Compounds
This thematic issue focuses on elucidating advanced synthetic strategies for bioactive compounds, with the primary objective of deepening understanding of the rational design and construction of target molecules. The exploration encompasses a diverse range of techniques, established name reactions, and cutting-edge synthetic methodologies. Specifically, the issue delves into the synthesis ...read more
Advances in Sustainable Synthesis and Applications of Cyclic Carbonates: From Green Chemistry to Advanced Materials
Cyclic carbonates have become a focus of attention because of their potential in sustainable chemistry, energy solutions, and advanced materials. Recent breakthroughs in their synthesis emphasize the use of CO₂ as a renewable feedstock, which is a step toward reducing carbon emissions. New catalytic processes, including both traditional metal catalysts ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Angiotensin II-Induced Signaling Pathways in Diabetes
Current Diabetes Reviews Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity:Role of Sympathetic Nerve Activity and Insulin Resistance
Current Diabetes Reviews Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic Complications
Current Medicinal Chemistry Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Rosuvastatin and Diabetes: When the Evidences Talk
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Vascular Pharmacology The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Flavonoids-mediated TLR4 Inhibition as a Promising Therapy for Renal Diseases
Combinatorial Chemistry & High Throughput Screening Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Current Diabetes Reviews Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets